Loading
LB Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Deep Track Biotechnology Master Fund, Ltd., was filed 16 Sept 2025.
LB Pharmaceuticals Inc: what insiders have been doing
This page follows insider dealings at LB Pharmaceuticals Inc as filed with SEC (Form 4), a company from the Health Care sector. 1 insider has disclosed 1 filing since 22 October 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Compared with its exchange (3,171 companies, median 24 filings), a count of 1 filing is below the norm. The full history, which starts in 2025, counts 5 purchases against no sales. The 10-K for the year ended 31 December 2025 shows -25.2 m USD of net income.
There has been no open-market purchase by an insider of LB Pharmaceuticals Inc for at least a year.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
12
Thresholds
n/a
Buy Volume
€51M
5 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDeep Track Biotechnology Master Fund, Ltd.2 buys
Vida Ventures GP III, L.L.C.2 buys
Pontifax Management 4 G.P. (2015) Ltd.1 buy
Since the insiders bought
- +158.4%Entry US$16.31 · Close at T+365 US$42.14
- +158.4%Entry US$16.31 · Close at T+365 US$42.14
- +158.4%Entry US$16.31 · Close at T+365 US$42.14
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate LB Pharmaceuticals Inc Strong Buy (bullish), based on 11 analysts. Average price target: US$58.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$38.81
Analyst consensus
11 analystsStrong buy
US$35.00Target US$58.00(+49%)US$80.00
Income statement
EBITDA-US$30.1M
Net income-US$25.2M0.0% margin
Valuation
PER (trailing)388.1x
PER (forward)-7.6x
P/Book3.3x
Balance sheet & cash
Market capUS$1.3B
Total debtUS$3.6M
Free Cash Flow-US$35.3M
Debt / Equity2%
Profitability & ownership
ROE-50.0%
ROA-30.0%
% insiders0.2%
% institutions102.4%
Last declaration on 9 June 2026
Declarations12 total
16,500 shares@ US$29.48880.031% mcap100.0% of flowCommon StockSEC144:0001972481-26-000189
▲
Same trade as the filing by Pontifax Management 4 G.P. (2015) Ltd., counted once
15M USD37SEC
1,000,000 shares@ US$15.00100.0% of flowCommon StockSEC:0001609805-25-000006:1
Canonical exit: 11 Dec 2025 (T+90)
2,000,000 shares@ US$15.0075.0% of flowCommon StockSEC:0002015536-25-000007:1
Canonical exit: 11 Dec 2025 (T+90)
666,666 shares@ US$15.0025.0% of flowCommon StockSEC:0002015536-25-000007:2
Canonical exit: 11 Dec 2025 (T+90)
1,000,000 shares@ US$15.00100.0% of flowCommon StockSEC:0001726334-25-000003:1
Canonical exit: 11 Dec 2025 (T+90)
332,566 shares@ US$15.0099.8% of flowCommon StockSEC:0001193125-25-204935:2
Canonical exit: 11 Dec 2025 (T+90)
767 shares@ US$15.000.2% of flowCommon StockSEC:0001193125-25-204935:3
Canonical exit: 11 Dec 2025 (T+90)
686,138 sharesCommon StockSEC:0002015536-25-000007:0
411,681 sharesCommon StockSEC:0001726334-25-000003:0
411,681 sharesCommon StockSEC:0001609805-25-000006:0
547,648 sharesCommon StockSEC:0001193125-25-204935:0
1,262 sharesCommon StockSEC:0001193125-25-204935:1
12 of 12 declarations
About LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a company listed on NASDAQ, specializing in the development of pharmaceutical solutions. It focuses on innovation in the healthcare sector.
